Decreased Ventilation and Hypoxic Ventilatory Responsiveness Are Not Reversed by Naloxone in Lhasa Residents with Chronic Mountain Sickness

Abstract
Persons with chronic mountain sickness (CMS) hypoventilate and are more hypoxemic than normal individuals, but the cause of the hypoventilation is unclear. Studies of 14 patients with CMS and 11 healthy age-matched control subjects residing in Lhasa, Tibet, China (3,658 m) were conducted to test the hypothesis that hypoventilation, blunted hypoxic ventilatory responsiveness (HVR), and hypoxic ventilatory depression of CMS were due to increased endogenous opioid production. Patients with CMS compared with control subjects exhibited hypoventilation (end-tidal carbon dioxide pressure [PETCO2] = 36.6 .+-. 1.0 versus 31.5 .+-. 0.5 mm Hg, p < 0.05), lower tidal volume (VT = 0.54 .+-. 0.02 versus 0.61 .+-. 0.02 ml BTPS, p < 0.05), blunted HVR (shape parameter A = 17 .+-. 8 versus 114 .+-. 22 mg Hg/L BTPS/min, p < 0.05), and a depressant effect of ambient hypoxia on ventilation (.DELTA.EPETCO2 with ute hyperoxia = -3.5 .+-. 0.5 versus -1.0 .+-. 0.6 mm Hg, p < 0.05). Reduced forced expiratory volume in 1 s to vital capacity ratios (FEV1/VC) and a higher proportion of cigarette smokers in the group of patients with CMS compared with control subjects suggested that at least some patients with CMS had mild airway obstructive lung disease. Naloxone infusion (0.14 mg/kg) to six patients with CMS did not change resting VT, PETCO2, HVR, or SaO2. Thus, although endogenous opioids were not implicated, the data suggested that blunted peripheral HVR and central hypoxic ventilatory depression reduced alveolar ventilation, and that alveolar hypoventilation together with chronic obstructive lung disease in some patients with CMS were responsible for the exaggerated hypoxemia characteristic of this disorder.